1. Search Result
Search Result
Results for "

Mitotic

" in MedChemExpress (MCE) Product Catalog:

177

Inhibitors & Agonists

3

Fluorescent Dye

2

Biochemical Assay Reagents

4

Peptides

1

MCE Kits

1

Inhibitory Antibodies

32

Natural
Products

3

Recombinant Proteins

9

Isotope-Labeled Compounds

10

Antibodies

4

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145803

    Microtubule/Tubulin Cancer
    KIF18A-IN-3 is a potent KIF18A inhibitor (IC50=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer .
    KIF18A-IN-3
  • HY-145802

    Microtubule/Tubulin Cancer
    KIF18A-IN-2 is a potent KIF18A inhibitor (IC50=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer .
    KIF18A-IN-2
  • HY-13674

    NSC 153858

    Microtubule/Tubulin Cancer
    Maytansine is a highly potent microtubule-targeted compound that induces mitotic arrest and kills tumor cells at subnanomolar concentrations .
    Maytansine
  • HY-110242

    Mps1 Apoptosis Cancer
    Mps-BAY2a is a monopolar spindle 1 (MPS1) inhibitor with an IC50 of 1 nM against human MPS1. Mps-BAY2a induces mitotic aberrations and apoptosis in cancer cells .
    Mps-BAY2a
  • HY-147092

    Microtubule/Tubulin Others
    Oryzalin is a dinitroaniline herbicide, binding to plant tubulin and inhibits microtubule (MT) polymerization in vitro. Oryzalin depolymerizes MTs and prevented the polymerization of new MTs at all stages of the mitotic cycle .
    Oryzalin
  • HY-145034

    Microtubule/Tubulin Inflammation/Immunology Cancer
    KIF18A-IN-1 is a mitotic kinesin KIF18A inhibitor extracted from patent WO2021026098A1 example 100-13. KIF18A-IN-1 exhibits anti-tumor activity .
    KIF18A-IN-1
  • HY-10971
    Alisertib
    40+ Cited Publications

    MLN 8237

    Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib
  • HY-P3480

    Fluorescent Dye Others
    H-Trp-Phe-Tyr-Ser(PO3H2)-Pro-Arg-pNA is a chromogenic substrate for Pin1. Pin1 is an essential and conserved mitotic peptidyl-prolyl isomerase, and can recognize the phosphoserine-proline bonds present in mitotic phosphoproteins .
    H-Trp-Phe-Tyr-Ser(PO3H2)-Pro-Arg-pNA
  • HY-14661

    Kinesin Cancer
    SB-743921 free base is a potent selective inhibitor of the mitotic kinesin KSP (Eg5), with a Ki of 0.1 nM. SB-743921 free base can induce mitotic arrest, block cell cycle progression, induce apoptosis, and can be used in the research of myeloma, leukemia and other diseases .
    SB-743921 free base
  • HY-10971A

    MLN 8237 sodium

    Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib sodium
  • HY-147092R

    Microtubule/Tubulin Others
    Oryzalin (Standard) is the analytical standard of Oryzalin. This product is intended for research and analytical applications. Oryzalin is a dinitroaniline herbicide, binding to plant tubulin and inhibits microtubule (MT) polymerization in vitro. Oryzalin depolymerizes MTs and prevented the polymerization of new MTs at all stages of the mitotic cycle .
    Oryzalin (Standard)
  • HY-119407

    Kinesin Cancer
    Terpendole E is a mitotic kinesin Eg5 inhibitor. Terpendole E inhibits both motor and microtubule-stimulated ATPase activities of human Eg5. Terpendole E induces formation of a monoastral spindle in M phase .
    Terpendole E
  • HY-161287

    HDAC Cancer
    HDAC6-IN-32 (compound 25202) is a selective and potent inhibitor of HDAC6. HDAC6-IN-32 blocks HDAC6 activity and interferes with microtubule dynamics, leading to SAC activation and prolonged mitotic arrest, ultimately leading to apoptosis in CRPC cells .
    HDAC6-IN-32
  • HY-50672

    Kinesin Apoptosis Lipoxygenase Cancer
    MK-0731 is a selective, non-competitive and allosteric kinesin spindle protein (KSP) inhibitor with an IC50 of 2.2 nM and a pKa of 7.6. MK-0731 is >20,000 fold selectivity against other kinesins. MK-0731 induces mitotic arrest and induces apoptosis in tumors. MK-0731 provides significant antitumor efficacy .
    MK-0731
  • HY-129478

    Caspase Bcl-2 Family CDK Cancer
    TC11 is a MCL1 degrader. TC11 is also a Caspase-9 and CDK1 activator. TC11 structurally relates to immunomodulatory agents as phenylphthalimide derivative. TC11 induces apoptotic death caused by degradation of MCL1 during prolonged mitotic arrest .
    TC11
  • HY-N7654

    Apoptosis Cancer
    (-)-Epipodophyllotoxin (2) is an antiproliferative agent against cancer cells isolated from American mayapple Podophyllum peltatum, with GI50s of 0.36 and 0.24 μM in HeLa cells and MCF-7 cells, respectively. (-)-Epipodophyllotoxin can inhibit mitotic spindle assembly in vitro .
    (-)-Epipodophyllotoxin
  • HY-W271064

    Fluorescent Dye Others
    1-Methylpyrene is a ubiquitous environmental pollutant and rodent carcinogen. Its mutagenic activity depends on sequential activation by various CYP and sulfotransferase (SULT) enzymes. 1-Methylpyrene induces chromosome loss and mitotic disturbance, proba
    1-Methylpyrene
  • HY-145827

    Microtubule/Tubulin Cancer
    KIF18A-IN-4 is a moderately potent ATP and microtubule (MT) noncompetitive KIF18A inhibitor (IC50=6.16 μM). KIF18A-IN-4 has selectivity against a large panel of mitotic kinesins and kinases, and does not show any direct effects on tubulin assembly. KIF18A-IN-4 exhibits anti-tumor activity .
    KIF18A-IN-4
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-P1103A

    CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-151971

    Aurora Kinase Polo-like Kinase (PLK) Cancer
    Aurora Kinases-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB, rather than inhibiting its phosphorylation of H3 at Ser10 .
    Aurora Kinases-IN-3
  • HY-136310
    PIP4K-IN-a131
    1 Publications Verification

    Others Cancer
    PIP4K-IN-a131 is PIP4K lipid kinases inhibitor, with IC50s of 1.9 µM and 0.6 µM for purified PIP4K2A and PIP4Ks, respectively. PIP4K-IN-a131 exhibits cancer-selective lethality via dual blockade of the lipid kinase PIP4Ks and mitotic pathways .
    PIP4K-IN-a131
  • HY-N11128

    Kinesin Cancer
    Solidagonic acid inhibits HSET motor activity by promoting the conversion from abnormal monopolar to bipolar spindles. Solidagonic acid suppresses fission yeast cell death and enables reversion of the mitotic spindles from a monopolar to bipolar morphology. Solidagonic acid showed the growth inhibitory activity on the seedlings of Lactuca sativa L. and Lolium multiflorum Lam .
    Solidagonic acid
  • HY-124761

    Polo-like Kinase (PLK) Autophagy Cancer
    Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC50=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (Kd= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors .
    Poloppin
  • HY-W058849

    AMPK mTOR Apoptosis Cancer
    MT 63-78 is a specific and potent direct AMPK activator with an EC50 of 25 μM. MT 63–78 also induces cell mitotic arrest and apoptosis. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects .
    MT 63-78
  • HY-148122

    p97 Cancer
    NW 1028 is a potent VCP/p97 inhibitor. NW 1028 targets the ND1L domain of p97 and inhibits the degradation of a p97-dependent reporter. NW 1028 has good binding affinity with Kd values of 100 and 285 nM for ND1L and full length p97, respectively. NW 1028 has the function of regulating the mitotic spindle of cells .
    NW 1028
  • HY-162518

    Kinesin Microtubule/Tubulin Cancer
    Eg5-IN-3 (5) is an Eg5 inhibitor that targets the novel allosteric pocket (α4/α6/L11). Eg5-IN-3 (5) causes tubulin assembly distortion with irregular morphology, resulting in a typical mitotic arrest similar to Monastrol (HY-101071A) .
    Eg5-IN-3
  • HY-110347

    Mps1 Cancer
    Mps1-IN-1 dihydrochloride is a potent and ATP-competitive Mps1 kinase inhibitor with an IC50 of 367 nM. Mps1-IN-1 dihydrochloride inhibit Mps1 mitotic kinase activity and abrogates spindle assembly checkpoint (SAC) function. Mps1-IN-1 dihydrochloride decreases the viability of both cancer and ‘normal’ cells .
    Mps1-IN-1 dihydrochloride
  • HY-13716
    Noscapine
    1 Publications Verification

    (S,R)-Noscapine

    Opioid Receptor Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier .
    Noscapine
  • HY-106423A

    CI-980; NSC 613862 isethionate; (S)-(-)-NSC 613862 isethionate

    Antifolate Microtubule/Tubulin Cancer
    Mivobulin (isethionate) (CI-980) is an orally active, brain-penetrant and potent folate antagonist and a tubulin-binding mitotic inhibitor. Mivobulin (isethionate) accumulates rapidly in L1210 and CHO/K1 cells to levels many-fold higher than those in the extracellular medium and efflux is also quite rapid. Mivobulin (isethionate) is promising for research of cancers .
    Mivobulin isethionate
  • HY-149086

    RAR/RXR Apoptosis PARP Bcl-2 Family Cancer
    BPA-B9 is a RXRα ligand and antagonist targeting the pRXRα-PLK1 interaction. BPA-B9 has excellent RXRα-binding affinity (KD=39.29 ± 1.12 nM). BPA-B9 inhibits the proliferation of cancer cells by inducing mitotic arrest and cell apoptosis .
    BPA-B9
  • HY-13716R

    Opioid Receptor Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Noscapine (Standard) is the analytical standard of Noscapine. This product is intended for research and analytical applications. Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier [4] .
    Noscapine (Standard)
  • HY-12137
    Volasertib
    20+ Cited Publications

    BI 6727

    Polo-like Kinase (PLK) Apoptosis Cancer
    Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .
    Volasertib
  • HY-12137A

    BI 6727 trihydrochloride

    Polo-like Kinase (PLK) Apoptosis Cancer
    Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .
    Volasertib trihydrochloride
  • HY-135960

    FGFR Apoptosis Cancer
    BO-264 is a highly potent and orally active transforming acidic coiled-coil 3 (TACC3) inhibitor with an IC50 of 188 nM and a Kd of 1.5 nM. BO-264 specifically blocks the function of FGFR3-TACC3 fusion protein. BO-264 induces spindle assembly checkpoint (SAC)-dependent mitotic arrest, DNA damage and apoptosis. BO-264 has broad-spectrum antitumor activity .
    BO-264
  • HY-113057

    Endogenous Metabolite Cancer
    3-Hydroxycapric acid is an inhibitor for mitotic progression.
    3-Hydroxycapric acid
  • HY-B0413
    Fenbendazole
    5 Publications Verification

    Parasite HIF/HIF Prolyl-Hydroxylase Microtubule/Tubulin Antibiotic Infection
    Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent and acts on helminthes primarily by binding to tubulin and disrupting the tubulin microtubule equilibrium. Fenbendazole stabilizes the transcriptional activator HIF-1α. Fenbendazole possesses an efficient anti-proliferative activity and induces apoptosis. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53 .
    Fenbendazole
  • HY-B0413S
    Fenbendazole-d3
    2 Publications Verification

    HIF/HIF Prolyl-Hydroxylase Parasite Microtubule/Tubulin Antibiotic Infection
    Fenbendazole-d3 is a deuterium labeled Fenbendazole. Fenbendazole-d3 is a HIF-1α agonist and activates the HIF-1α-related GLUT1 pathway. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53[1][2][3][4].
    Fenbendazole-d3
  • HY-B0413R

    Parasite HIF/HIF Prolyl-Hydroxylase Microtubule/Tubulin Antibiotic Infection
    Fenbendazole (Standard) is the analytical standard of Fenbendazole. This product is intended for research and analytical applications. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent and acts on helminthes primarily by binding to tubulin and disrupting the tubulin microtubule equilibrium. Fenbendazole stabilizes the transcriptional activator HIF-1α. Fenbendazole possesses an efficient anti-proliferative activity and induces apoptosis. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53 .
    Fenbendazole (Standard)
  • HY-147006

    Others Cancer
    MT-VC-ZD02044 is a cytotoxic and anti-mitotic agent .
    MT-VC-ZD02044
  • HY-13649
    Indibulin
    1 Publications Verification

    ZIO 301; D 24851

    Microtubule/Tubulin Apoptosis Neurological Disease Cancer
    Indibulin (ZIO 301), an orally applicable inhibitor of tubulin assembly, shows potent anticancer activity with a minimal neurotoxicity. Indibulin reduces inter-kinetochoric tension, produces aberrant spindles, activates mitotic checkpoint proteins Mad2 and BubR1, and induces mitotic arrest and apoptosis .
    Indibulin
  • HY-N0282
    Demecolcine
    3 Publications Verification

    Microtubule/Tubulin Apoptosis Inflammation/Immunology Cancer
    Demecolcine is a potent mitotic inhibitor with an IC50 value of 2.4 μM for inhibition of tubulin polymerization. Colcemid (Demecolcine) can interact with tubulin dimers to induce anti-mitotic action and inhibit microtubule growth. Colcemid (Demecolcine) can be used for inflammatory disorders and cancer research .
    Demecolcine
  • HY-15000

    Kinesin Cancer
    EMD534085 is a potent and selective inhibitor of the mitotic kinesin-5 with an IC50 of 8 nM.
    EMD534085
  • HY-12069
    SB-743921 hydrochloride
    3 Publications Verification

    Kinesin Cancer
    SB-743921 hydrochloride is a potent inhibitor of the mitotic kinesin KSP (Eg5), with a Ki of 0.1 nM.
    SB-743921 hydrochloride
  • HY-12053A
    Vinorelbine ditartrate
    10+ Cited Publications

    KW-2307; Nor-5'-anhydrovinblastine ditartrate

    Microtubule/Tubulin Autophagy Cancer
    Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.
    Vinorelbine ditartrate
  • HY-15162A
    MMAE-d8
    5+ Cited Publications

    Monomethyl auristatin E-d8; Deuterated labeled MMAE

    Microtubule/Tubulin ADC Cytotoxin Cancer
    MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
    MMAE-d8
  • HY-161112

    Kinesin Others
    LG157 is a potent inhibitor of mitotic kinesin-like protein 2 (MKLP2) .
    LG157
  • HY-12053

    KW-2307 base

    Microtubule/Tubulin Autophagy Cancer
    Vinorelbine is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.
    Vinorelbine
  • HY-122249

    Microtubule/Tubulin Cancer
    MT-7 is a potent mitotic inhibitor. MT-7 shows antiproliferative activity. MT-7 induces cell cycle arrest at G2/M phase. MT-7 induces specific, reversible mitotic arrest and inhibits the polymerization of cellular microtubules .
    MT-7
  • HY-101071A
    Monastrol
    4 Publications Verification

    (±)-Monastrol

    Kinesin Apoptosis Cancer
    Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5 with an IC50 value of 14 μM.
    Monastrol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: